正规·beat365旧版(官方VIP认证)-App Store

Suzhou Ribo announces the first siRNA-based FXI targeting anti-thrombotic agent (RBD4059) to receive HREC approval for first-in-human study in Australia

Suzhou Ribo Life Science Co., Ltd. announces the first siRNA-based FXI targeting anti-thrombotic agent (RBD4059) to receive HREC approval for first-in-human study in Australia.

Ribo Announces Successful Passing EU GMP Audit.

Suzhou Ribo Life Science Co., Ltd. announced today that it has recently received the European Union Qualified Person Declaration (QPD) from the Qualified Person based on the positive results of the EU GMP audit conducted for its oligonucleotide manufacturing facilities located in Kunshan, China.

Ribo Announces China CDE Approval of Clinical Trial Application of RBD7022 First-In-Human Clinical Trial in China for Treatment of Hyperlipidemia.

Suzhou Ribo Life Science Co., Ltd. announced the company has received the approval from the CDE of the NMPA for the clinical trial application of its innovative PCKS9 targeting oligonucleotide drug product RBD7022 to conduct the First-In-Human clinical trial in China.

Ribo Closed $40M Series E1 Financing to support global development of the diversified pipelines and continuous advancement of siRNA technologies.

Ribocure Pharmaceuticals Moves Into GoCo Clinic - Putting North Europe in the Spotlight Within Oligonucleotide Therapeutics

Ribocure Pharmaceuticals, the first overseas R&D center of Ribo based in Sweden, announces it will move in and open a clinical trial unit at GoCo Clinic - where both patient care and research will be conducted when it’s ready in the spring of 2023.